Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Liggett Vector Brands is the sales, marketing, and distribution arm for Liggett Group and Vector Tobacco, which are subsidiaries of Vector Group. In October 2024, the company was acquired by Japan Tobacco (JT) in a transaction valued at approximately $2.4 billion. While primarily a tobacco manufacturer, the company has historically engaged in biotechnology through its development of genetically modified tobacco plants designed to produce low-nicotine cigarettes under the Quest brand. These efforts utilized plant genetic engineering to target nicotine biosynthesis pathways, representing a significant intersection between agricultural biotechnology and consumer products. Currently, the company focuses on the discount cigarette market in the United States, managing a portfolio that includes brands such as Pyramid, Eagle 20's, and Eve.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Liggett Vector Brands.